NMD4C members awarded CIHR grants for oculopharyngeal dystrophy, spinal muscular atrophy research
The NMD4C is happy to share that two project applications from NMD4C members on oculopharyngeal dystrophy (OPMD) and spinal muscular atrophy (SMA) have been awarded Canadian Institute of Health Research (CIHR) research grants in their recent round of funding decisions!
A comprehensive study of the natural history of OPMD: An essential step towards clinical trial readiness and evidence-based interventions
Led by NMD4C investigator Dr. Cynthia Gagnon, this project has been awarded $820, 846 over a 5-year period, and includes fellow NMD4C investigators Dr. Bernard Brais as a principal investigator, Dr. Hanns Lochmüller as a co-applicant, Dr. Homira Osman as a collaborator and Dr. Élise Duchesne, early-career member of the NMD4C, as an investigator. Other NMD4C members on this project include Dr. Luc Hébert as a principal investigator, Dr. Benjamin Gallais as a co-applicant, Claudia Côté and Dr. Xavier Rodrigue as collaborators, and project collaborators Dr. Djamal Barbiche, Dr. Nancy Presse, and Dr. Jean-Denis Brisson.
The study involves four data collection sites (Saguenay, Québec, Montréal and Ottawa) and will address the impact of OPMD over time in the lives of those affected by these neuromuscular disorders. The study will involve the use of NMD4C-related activities including the Canadian Neuromuscular Disease Registry, biobanking resources, and the network’s knowledge translation expertise.
In addition to dysphagia, the team will document several characteristics related to their physical performances, such as walking capacities and muscle strength. Also, the study will look at their participation in daily activities, such as the ability to move in their house and communities, and to perform sports and leisure activities. The research team will also be able to select the best instruments to assess the key problems in this disorder such as muscle weakness and fatigue.
This study will provide essential data to help speed up therapeutic trials in this population by documenting natural history and informing outcome measures selection.
The scientific summary can be found here!
Extracellular vesicles as a biomarker and therapeutic for Spinal Muscular Atrophy
Led by NMD4C member Dr. Robin Parks, this project has been awarded $960,076 over a 5-year period and includes Dr. Rashmi Kothary (NMD4C steering committee member), Dr. Jodi Warman Chardon (NMD4C steering committee member) and Dr. Panayotis Vacratsis from the University of Windsor as co-investigators.
SMA is a devastating disorder primarily affecting newborns and young children, caused by reduced levels of the survival motor neuron (SMN) protein. Although normally present in all cells of the body, reduced levels of SMN protein results in degeneration of motor neurons, leading to muscle weakness and, in the case of severe disease, death.
A small proportion of SMN protein is naturally released by cells in small “bubbles” called extracellular vesicles (EV). This study will evaluate whether analysis of EV isolated from patient blood can be used as a marker for the disease state, which may allow the development of a blood test to monitor the effectiveness of therapeutics.
The NMD4C are happy to see members obtaining positive funding decisions in a competitive application process, and would like to congratulate them on their success! The network is proud to have leading Canadian neuromuscular researchers as members and will continue the network’s work in supporting the neuromuscular research community in Canada.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.